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S UMMA R Y
BACKGROUND : Understanding of the effects of human
immunodeficiency virus (HIV) infection and antiretro-
viral treatment (ART) on Mycobacterium tuberculosis
transmission dynamics remains limited. We undertook a
cross-sectional study among household contacts of
smear-positive pulmonary tuberculosis (TB) cases to
assess the effect of established ART on the infectiousness
of TB.
ME T HOD : Prevalence of tuberculin skin test (TST)
positivity was compared between contacts of index cases
aged 2–10 years who were HIV-negative, HIV-positive
but not on ART, on ART for,1 year and on ART for71
year. Random-effects logistic regression was used to take
into account clustering within households.
R E SU LT S : Prevalence of M. tuberculosis infection in
contacts of HIV-negative patients, HIV-positive patients
on ART71 year and HIV-positive patients not on ART/
on ART,1 year index cases was respectively 44%, 21%
and 22%. Compared to contacts of HIV-positive index
cases not on ARTor recently started on ART, the odds of
TST positivity was similar in contacts of HIV-positive
index cases on ART 71 year (adjusted OR [aOR] 1.0,
95%CI 0.3–3.7). The odds were 2.9 times higher in child
contacts of HIV-negative index cases (aOR 2.9, 95%CI
1.0–8.2).
CONC LU S I ON S : We found no evidence that established
ART increased the infectiousness of smear-positive,
HIV-positive index cases.
K E Y WORD S : M. tuberculosis infection; infectiousness;
tuberculosis; antiretroviral treatment; HIV
THE HUMAN IMMUNODEFICIENCY VIRUS
(HIV) pandemic continues to challenge global tuber-
culosis (TB) control,1,2 yet our understanding of the
effects of HIV and antiretroviral treatment (ART) on
Mycobacterium tuberculosis transmission dynamics
remains limited.3–7
In HIV-positive individuals, ART reduces TB
incidence across all CD4 cell counts;8 nevertheless,
despite long-term ART, TB incidence remains higher
in HIV-positive than in HIV-negative people in both
high and low TB burden settings.9,10 As life expec-
tancy is greatly extended by ART, the cumulative
lifetime risk of TB among HIV-positive people
remains very high.9 Although HIV-positive TB
patients with advanced immunosuppression are less
likely to transmit to household contacts than their
HIV-negative counterparts,11–17 partly due to lower
sputum bacillary load,11,16,17 ART may increase the
infectiousness of TB by modifying clinical manifesta-
tions, making them more similar to those in HIV-
negative patients.18,19
Concerns have been raised that increased life
expectancy and possible increased infectiousness
due to ART might increase TB incidence at a
population level.20 This might be negated by reduced
HIV transmission;21,22 however, a rebound in TB
incidence, exceeding present pre-ART roll-out levels,
is possible if good adherence to ART is not
sustained.23 Programmatic data from South Africa,
Malawi and Zimbabwe have shown a reduction in TB
incidence, as inferred from trends in TB case
notification, in association with ART scale-up.24,25
However, short-term reductions in TB incidence may
be due to protection from progression to disease
rather than a reduction in M. tuberculosis transmis-
sion.
We examined the effect of ART on M. tuberculosis
transmission by measuring the prevalence of M.
tuberculosis infection among child contacts of adult
smear-positive TB cases.
METHODS
Study setting
Karonga District, northern Malawi, is predominantly
rural, with an adult HIV prevalence of 9% and new
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smear-positive TB incidence of 87 per 100 000 adults
per year;26 60% of TB cases are HIV-positive.26 The
first ART clinic opened in 2005, and by 2012, 16
clinics in the district were certified to initiate and
provide ART.27
Study design
A cross-sectional household study of all diagnosed
smear-positive TB cases in the district was conducted
from January 2013 to April 2015. Households were
eligible if a smear-positive case had lived there for at
least 2 weeks after the onset of symptoms and before
initiation of treatment. Bacteriological, demographic
and clinical (including HIV and ART status) data
from all patients starting anti-tuberculosis treatment
in the district have been collected in a TB case cohort
study since 1988 (described elsewhere).26,28
Households were visited approximately 6 weeks
after TB diagnosis of an index case (date of first
smear-positive sputum). All children aged 2–10 years
residing in the household were included. A tuberculin
skin test (TST) was administered and read according
to standard international guidelines29 using 2 inter-
national units of RT23 (Statens Serum Institute,
Copenhagen, Denmark), and induration was mea-
sured 48–72 h later. A positive TST was defined as
induration 710 mm. Children aged ,2 years were
excluded to minimise misclassification of infection
status with false-positive TST due to recent bacille
Calmette-Gue´rin (BCG) vaccination.30
A questionnaire was completed which included
data on demographics, BCG vaccination status,
exposure to index case (whether index case was
mother, duration of sleeping in same room and of
living in the same household while index case was
symptomatic), and household characteristics (num-
ber of residents, socio-economic indicators including
quality of dwelling place). A composite score for
household socio-economic status was created using
head of household employment, number of assets,
food security and availability of soap, and a
composite score for quality of dwelling place was
based on building materials, type of roof, number of
rooms, water source, presence of glass windows,
electricity and latrine type.
Any child with symptoms suggestive of TB (fever,
weight loss, failure to thrive, night sweats or cough)
was reviewed by a clinician and referred to the district
hospital where appropriate. All children aged ,5
years without evidence of active disease were
commenced on 6-month isoniazid preventive treat-
ment (5 mg/kg once daily), irrespective of TST
induration size, in accordance with Malawi National
TB Programme guidelines.31
Ethics approval
The study was approved by the Malawi National
Health Sciences Research Committee, Lilongwe, Ma-
lawi (#1049) and the London School of Hygiene &
Tropical Medicine Ethics Committee, London, UK
(#6285). At the time of study recruitment, smear-
positive pulmonary TB patients were asked for written
consent to visit their household(s) to screen household
members for infection and disease. Written informed
consent was then obtained from a parent or guardian of
each participating child at the time of household visit.
Statistical analysis
Prevalence of TST positivity was compared between
household contacts by HIV and ART status of the
index case to distinguish those not on ARTor on ART
for ,1 year from those on ART for 71 year at TB
diagnosis. We performed univariable analyses for
covariates known to be risk factors forM. tuberculosis
infection, and these were assessed as confounders of
the association between HIV/ART status and TST
positivity, first individually and then in a multivariable
model, using random-effects logistic regression to
account for clustering within households.
Sputum smear grade and duration of symptoms
were not included in the initial multivariable model as
they were considered to be on the causal pathway
between HIV/ART status and prevalence of TST
positivity in the child contact. These were examined
as mediators of the association in subsequent models.
Sensitivity analyses
The analysis was repeated 1) grouping all patients on
ART irrespective of time on ART, 2) separating
patients on ART for72 years and 3) using a TST cut-
off 715 mm.
RESULTS
A total of 388 child contacts of 187 index cases were
eligible for inclusion (Figure 1), 309 of whom had a
TST placed and read within 48–72 h (80%; 153 index
cases). As HIV/ART status was missing for three
index cases (seven contacts), 302 child contacts of
150 index cases were included in the final analysis.
One hundred and seventy-seven children (58.4%)
had no induration; the frequency distribution of those
children with non-zero TST induration (n ¼ 125) is
shown in Figure 2.
Index case characteristics
Of the 150 index cases, 63% were male. The median
age was 33.6 years (interquartile range [IQR] 28.2–
39.3) in female index cases and 37.6 years (IQR 30.6–
44.9) in male index cases; 22% of index cases were on
ARTat TB diagnosis, with a median duration on ART
of 2.8 years (IQR 1.2–4.5; n ¼ 33). Table 1 shows
index case characteristics by HIV/ART status. The
median duration of symptoms before TB diagnosis
(by self-report) was shortest in HIV-positive patients
on ART 71 year (8.3 weeks, IQR 7.0–16.3).
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Tuberculin skin test positivity in child contacts
The prevalence of TST positivity among all child
contacts was 34.4%. TST positivity in child contacts
ofHIV-positive index cases not on ARTwas 23.1% (15/
65); as there were only 11 child contacts of 8 HIV-
positive index cases on ART for,1 year (TST positivity
18.2%), this category was combined with the HIV-
positive index cases not on ART. TST positivity was
respectively 44.1% (75/170), 21.4% (12/56) and
22.4% (17/76) in contacts of index cases who were
HIV-negative, HIV-positive on ART71 year and HIV-
positive not on ART/on ART for ,1 year (Table 2).
Factors associated with TST positivity in child
contacts included HIV/ART status of index case, sex
of index case, whether the index case was the mother,
index case sputum smear grade and degree of
exposure of contact (Table 2).
Compared to contacts of HIV-positive index cases
Figure 1 Study flowchart: TB case through to child contact TST data included in analysis. HIV¼
human immunodeficiency virus; ART¼antiretroviral therapy; TB¼ tuberculosis;¼ negative;þ¼
positive.
Figure 2 Histogram illustrating the frequency distribution of non-zero induration in child
contacts (n¼ 125).
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not on ART or on ART for ,1 year, the odds of a
positive TSTwere higher in contacts of HIV-negative
index cases (crude odds ratio [OR] 4.3, 95%CI 1.4–
13.1, reducing to OR 2.9, 95%CI 1.0–8.2 after
adjustment for sociodemographic factors), but not in
contacts of HIV-positive index cases who had been on
ART for 71 year (crude OR 1.1, 95%CI 0.3–4.6,
adjusted OR [aOR] 1.0, 95%CI 0.3–3.7; Table 2).
Further adjustment was used to assess the effect of
factors that may be on the causal pathway. Although
adjusting for duration of symptoms (Model 2A, Table
3) made little difference to the odds of TST positivity
in contacts of HIV-negative index cases, adjusting for
smear grade (Model 2B) reduced the association
(aOR 2.2, 95%CI 0.8–6.3). No association of TST
positivity with ART duration was observed among
contacts of HIV-positive index cases in any model
(Table 3).
The results of the sensitivity analyses are also
shown in Table 3. Using a cut-off TST of 715 mm,
regrouping those on ART ignoring duration, or
separating those on ART .2 years, made little
difference to the results
DISCUSSION
We found no evidence that child contacts of HIV-
positive TB patients on ARTwere more likely to have
a positive TST than child contacts of HIV-positive TB
patients not on ART. However, child contacts of HIV-
negative individuals had nearly three times the odds
of having a positive TST than child contacts of HIV-
positive TB patients not on ART; this was partly
explained by differences in the degree of smear
positivity.
Some TB household contact studies have found no
difference in infectiousness between HIV-positive TB
patients compared to HIV-negative TB patients if
HIV-positive index cases were less immunosup-
pressed (CD4 .250 cells/mm3)16 or were smear-
positive and/or had cavitary disease.17 Heterogeneity
observed in estimates of infectiousness of HIV-
positive TB patients compared to HIV-negative TB
patients has been well-described, although no studies
to date have examined the effect of ART status of the
HIV-positive index case. Possible reasons for hetero-
geneity include differences in patient eligibility
(smear-positive only vs. all TB patients), study
settings (high vs. low HIV and TB background
prevalence), household contacts screened for M.
tuberculosis infection (adults and children vs. chil-
dren only) and study-related biases, such as exposure
assessment bias and recall bias.16,17,32,33 Study
calendar period may also influence estimates of
infectiousness, as the degree of immunosuppression
of HIV-positive TB cases on a population level will be
a function of the maturity of the HIV epidemic and
the time since roll-out of ART.
The lack of evidence for increased infectiousness in
TB patients established on ART compared to those
not on ART in our study may be due to earlier
diagnosis, resulting in a shorter duration of infec-
tiousness. However, adjusting for duration of symp-
toms in Model 2A did not alter the odds of a positive
TST in contacts of index cases who had been on ART
for 71 year. This might be due to the fact that the
duration of symptoms at the time of TB diagnosis is
notoriously difficult to recall accurately. It should be
noted that a contemporaneous study of attendance at
the HIV/ART clinic undertaken at the Karonga
District Hospital found that HIV-positive individuals
on ARTattended the clinic much more regularly than
those not on ART; the median number of visits per
year was 5 (IQR 4–6) among ART patients and 1
(IQR 1–2) among HIV patients not on ART
(unpublished data). This gives much greater oppor-
tunity for early diagnosis of TB. Another reason for
the absence of evidence of increased infectiousness in
TB patients established on ART may be that in our
north Malawi population the effect of ART was
Table 1 Index case characteristics by HIV/ART status of the index case (n¼ 150)
Case characteristics
HIV/ART status of index case
HIV
(n ¼ 82)
n (%)
HIVþ,
ART 71 year
(n ¼ 25)
n (%)
HIVþ,
ART ,1 year
(n ¼ 8)
n (%)
HIVþ
no ART
(n ¼ 35)
n (%)
Male 50 (61.7) 14 (56.0) 5 (62.5) 25 (71.4)
Age, years, mean 6 SD 36.1 6 14.7 39.9 6 6.1 36.1 6 4.8 36.7 6 8.7
Index case mother 15 (18.3) 7 (28.0) 2 (25.0) 5 (14.3)
Smear grade
Scanty 2 (2.5) 3 (12.0) 1 (12.5) 4 (11.4)
þ1 11 (13.4) 4 (16.0) 2 (25.0) 9 (25.7)
þ2 27 (32.9) 9 (36.0) 3 (37.5) 4 (11.4)
þ3 42 (51.2) 9 (36.0) 2 (25.0) 18 (51.5)
Duration of symptoms,
weeks, median [IQR] 13.2 [7.6–20.6] 8.3 [7.0–16.3] 18.6 [8.2–28.6] 12.4 [8.0–19.7]
HIV¼human immunodeficiency virus; ART¼antiretroviral therapy;¼negative;þ¼positive; SD¼ standard deviation;
IQR¼ interquartile range.
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Table 2 Demographic and clinical characteristics of index case and contact: risk factors for TST
positivity (n¼ 302)
Characteristics
TST 710 mm
(n ¼ 302)
n/N (%)
Crude OR
(95%CI) P value
Index case
HIV/ART status
HIVþ, no ART/ART ,1 year 17/76 (22.4) 1 0.009
HIVþ, on ART 71 year 12/56 (21.4) 1.1 (0.3–4.6)
HIV 75/170 (44.1) 4.3 (1.4–13.1)
Sex
Female 52/116 (44.8) 1 0.01
Male 52/186 (28.0) 0.3 (0.1–0.8)
Age, years
,30 35/86 (41.9) 1 0.3
30–44 53/156 (34.0) 0.6 (0.2–1.7)
745 15/60 (25.0) 0.3 (0.1–1.3)
Index case relationship
Not mother 70/243 (28.8) 1 0.002
Mother 34/59 (57.6) 4.7 (1.7–13.0)
Smoker
No 72/207 (34.8) 1 0.8
Yes 32/95 (33.7) 0.9 (0.3–2.5)
Sputum smear grade
Scanty 1/19 (5.3) 0.02 (0.001–0.5) 0.005
þ1 12/57 (21.1) 0.2 (0.06–0.8)
þ2 35/92 (38.0) 0.7 (0.2–1.9)
þ3 56/134 (41.8) 1
Duration of symptoms, weeks
,8 34/118 (28.8) 1 0.1
78 70/184 (38.0) 2.1 (0.8–5.6)
Contact
Sex
Female 52/148 (35.1) 1 0.6
Male 52/154 (33.8) 0.8 (0.4–1.7)
BCG scar*
No 17/41 (41.5) 1 0.3
Yes 82/248 (33.1) 0.6 (0.2–1.7)
Age, years
2–3 30/75 (40.0) 1 0.7
4–5 24/62 (38.7) 1.2 (0.4–3.3)
6–7 22/77 (28.6) 0.7 (0.3–1.7)
78 28/88 (31.8) 0.8 (0.3–1.9)
Degree of exposure to index case while symptomatic
Resident 44/175 (25.1) 1 0.008
Sleep in same room 630 days 16/46 (34.8) 1.5 (0.5–4.3)
Sleep in same room .30 days 42/81 (51.9) 4.0 (1.7–10.4)
Household
Adults, n
1–2 42/101 (41.6) 1 0.3
3–4 47/139 (33.8) 0.6 (0.2–1.7)
75 15/62 (24.2) 0.3 (0.1–1.3)
Socio-economic status
Lowest score 54/148 (36.5) 1 0.08
Middle 33/80 (41.3) 1.3 (0.4–3.9)
Highest score 17/74 (23.0) 0.3 (0.09–1.1)
Quality of dwelling score
Lowest 28/64 (43.8) 1 0.1
Middle 45/118 (38.1) 0.6 (0.2–2.1)
Highest 31/117 (26.5) 0.3 (0.08–1.0)
Crowding, persons/room
1–2 45/131 (34.4) 1 0.6
3–4 45/138 (32.6) 1.0 (0.4–2.7)
75 14/33 (42.2) 2.3 (0.5–11.7)
* BCG scar status missing for 13 child contacts.
TST ¼ tuberculin skin test; OR ¼ odds ratio; CI ¼ confidence interval; HIV ¼ human immunodeficiency virus; ART ¼
antiretroviral therapy;þ¼ positive;¼ negative; BCG¼ bacille Calmette-Gue´rin.
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masked by the degree of immunodeficiency of the
index case, because ART is started in individuals with
more advanced HIV infection.
CD4 cell count testing is not routinely performed in
Karonga, resulting in the absence of a biological
marker for the level of immunosuppression of HIV-
positive TB patients and degree of immune reconsti-
tution in those established on ART in this study.
Limitations of our study also include the absence of
radiological data to assess the extent of lung
cavitation by HIV/ART status. These data would
have helped to interpret the apparent lack of effect of
ART on infectiousness. Knowledge of the HIV status
of the child contacts would also have strengthened
this study, as an HIV-positive child with advanced
immunosuppression may be more likely to have a
false-negative TST than an HIV-negative child, and
an HIV-positive child is more likely to be resident in
the household of an HIV-positive index case. This is
one potential explanation for the lower prevalence of
M. tuberculosis infection in child contacts of index
cases with HIV infection, irrespective of ART status,
found in this study. However, ART for prevention of
mother-to-child transmission is widely used and the
proportion of infected children will be very low.
CONCLUSION
We found a higher prevalence of M. tuberculosis
infection among child contacts of HIV-negative TB
patients than in contacts of HIV-positive index cases,
irrespective of ART status. We found no evidence to
suggest that HIV-positive index cases on ART for71
year at TB diagnosis were more likely to transmit
than other HIV-positive index cases. The frequent
contact of HIV-positive individuals on ART with the
health services, leading to prompt diagnosis of TB,
may mitigate the effects of any increase in infectious-
ness. Further studies are required to definitively
establish whether ART has a biological effect on the
infectiousness of HIV-positive TB patients.
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R E´ S U M E´
CONT EX T E : La compre´hension des effets du virus de
l’immunode´ficience humaine (VIH) et du traitement
antire´troviral (ART) sur les dynamiques de transmission
de Mycobacterium tuberculosis reste limite´e. Nous
avons entrepris une e´tude transversale aupre`s des
contacts domiciliaires de cas de tuberculose (TB)
pulmonaire a` frottis positif afin d’e´valuer les effets de
la mise en œuvre de l’ART sur la contagiosite´ de la TB.
M E´ THODE : La pre´valence de la positivite´ du test cutane´
a` la tuberculine (TST) a e´te´ compare´e entre les contacts
aˆge´s de 2 a` 10 ans de cas index qui e´taient VIH ne´gatifs,
VIH positifs mais pas sous ART, sous ART depuis moins
d’un an et sous ART depuis un an ou plus. Une
re´gression logistique a` effets ale´atoires a e´te´ utilise´e
afin de tenir compte du regroupement au sein des foyers.
R E´ S U LTAT S : La pre´valence de l’infection a` M.
tuberculosis parmi les contacts des cas index VIH
ne´gatifs, VIH positifs sous ART depuis un an ou plus
et VIH positifs pas sous ART/sous ART depuis moins
d’un an a e´te´ de 44%, 21% et 22%, respectivement.
Compare´s aux contacts des cas index VIH positifs pas
sous ART ou seulement mis sous ART re´cemment, les
risques de positivite´ du TST ont e´te´ similaires chez les
contacts des cas index VIH positifs sous ART depuis un
an ou plus (OR ajuste´ [ORa] 1,0 ; IC95% 0,3–3,7). Les
risques ont e´te´ 2,9 fois plus e´leve´s chez les enfants
contacts de cas index VIH ne´gatifs (ORa 2,9 ; IC95%
1,0–8,2).
CONC LU S I ON : Nous n’avons pas trouve´ d’e´le´ments en
faveur d’une augmentation de la contagiosite´ des cas
index a` frottis positif et VIH positifs a` la suite de la mise
en route de l’ART.
R E S UM E N
MAR CO D E R E F E R E N C I A: La comprensio´n de los
efectos de la infeccio´n por el virus de la
inmunodeficiencia humana (VIH) y el tratamiento
antirretrovı´rico (TAR) en la dina´mica de la transmisio´n
de Mycobacterium tuberculosis es au´n incompleta. Se
emprendio´ un estudio transversal de los contactos
domiciliarios de casos de tuberculosis (TB) pulmonar
con baciloscopia positiva, con el fin de examinar el
efecto de recibir el TAR, sobre la contagiosidad de la TB.
M E´ TODO: Se comparo´ la prevalencia de positividad de
la prueba cuta´nea de la tuberculina en los contactos de 2
a 10 an˜os de edad de los casos iniciales de TB que eran,
ya sea, negativos frente al VIH, positivos frente al VIH y
no recibı´an TAR, positivos y que recibı´an TAR desde
hacı´a menos de un an˜o o positivos frente al VIH y en
TAR desde hacı´a un an˜o o ma´s. Mediante un modelo de
regresio´n logı´stica de efectos aleatorios se puso de
manifiesto la presencia de conglomerados en los
domicilios.
R E SU LTADOS: La prevalencia de infeccio´n tuberculosa
en los contactos de los casos negativos frente al VIH fue
44%, en los casos positivos frente al VIH que recibı´an
TAR desde hacı´a un an˜o o ma´s fue 21% y en los casos
positivos frente al VIH que no recibı´an TAR o en TAR
durante menos de un an˜o fue 22%. Al comparar los
contactos de los casos iniciales positivos frente al VIH
que no recibı´an TAR o que lo habı´an comenzado
recientemente, la posibilidad de obtener un resultado
positivo de la prueba tuberculı´nica fue equivalente a la
posibilidad de los contactos de casos positivos frente al
VIH que recibı´an TAR desde hacı´a un an˜o o ma´s
(cociente de posibilidades ajustado [aOR] 1,0; IC95%
0,3 a 3,7). La posibilidad fue 2,9 veces ma´s alta en los
nin˜os que eran contactos de casos iniciales de TB
negativos frente al VIH (aOR 2,9; IC95% 1,0 a 8,2).
CONC LU S I O´ N: No se encontraron pruebas de que el
hecho de recibir el TAR aumente la contagiosidad de los
casos iniciales de TB con baciloscopia positiva que son
positivos frente al VIH.
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